1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Drugs In Development, 2022, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 11, 12, 1, 17, 10 and 1 respectively.
Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Axial Spondyloarthritis - Overview
- Axial Spondyloarthritis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Axial Spondyloarthritis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Axial Spondyloarthritis - Companies Involved in Therapeutics Development
- Axial Spondyloarthritis - Drug Profiles
- Axial Spondyloarthritis - Dormant Projects
- Axial Spondyloarthritis - Discontinued Products
- Axial Spondyloarthritis - Product Development Milestones
- Featured News & Press Releases
- Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults
- Aug 08, 2022: Lilly's Taltz (ixekizumab) now available in new, citrate-free formulation to reduce injection site pain for improved patient experience
- Jul 29, 2022: RINVOQ (upadacitinib) approved by European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis
- Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the National Medical Products Administration of China
- Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
- Jul 20, 2022: Health Canada approves AbbVie's RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis
- Jun 27, 2022: CHMP recommends approval of Upadacitinib (RINVOQ) for the treatment of adults with active non-radiographic axial spondyloarthritis
- Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
- Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
- May 23, 2022: First presentations of phase 3 data for Bimekizumab across the full spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
- May 02, 2022: FDA grants approval for AbbVie's Rinvoq to treat ankylosing spondylitis
- Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Canada
- Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
- Jan 18, 2022: Positive top-line results for bimekizumab in phase 3 non-radiographic axial spondyloarthritis study
- Jan 07, 2022: AbbVie submits applications for Upadacitinib (RINVOQ) in non-radiographic axial spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Axial Spondyloarthritis, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Axial Spondyloarthritis - Dormant Projects, 2022
- Axial Spondyloarthritis - Discontinued Products, 2022
- Number of Products under Development for Axial Spondyloarthritis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- AbbVie Inc
- Akeso Inc
- AstraZeneca Plc
- Avesthagen Ltd
- Beijing Eastern Biotech Co Ltd
- Bio-Thera Solutions Ltd
- Biocad
- Biogen Inc
- Bioviz Technologies Pvt Ltd
- BioXpress Therapeutics SA
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Celltrion Inc
- Clover Biopharmaceuticals Ltd
- DNX Biopharmaceuticals Inc
- Dyadic International Inc
- Eli Lilly and Co
- Enzene Biosciences Ltd
- Foshan Rexie Biotechnology Co Ltd
- FunPep Co Ltd
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- Huabo Biopharm (Shanghai) Co Ltd
- Hualan Biological Engineering Inc
- Iltoo Pharma
- Immunwork Inc
- Izana Bioscience Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- Livzon Pharmaceutical Group Co Ltd
- Luye Pharma Group Ltd
- Lynk Pharmaceutical Hangzhou Co Ltd
- Mabpharm Ltd
- MoonLake Immunotherapeutics
- Mycenax Biotech Inc
- NeuClone Pty Ltd
- Nimbus Therapeutics LLC
- North China Pharmaceutical Group New Drug Research and Development Co Ltd
- Novartis AG
- Outlook Therapeutics Inc
- Pharmapraxis
- PKU V-Ming (Hefei) Biologics Co Ltd
- Qilu Pharmaceutical Co Ltd
- Sandoz International GmbH
- Shandong Danhong Pharmaceutical Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Novamab Biopharmaceuticals Co Ltd
- Siam Bioscience Co Ltd
- SinoCelltech Group Ltd
- siRNAgen Therapeutics Corp
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Tianjin Hemay Pharmaceutical Co Ltd
- UCB SA
- Valin Technologies Ltd
- Wuhan Institute of Biological Products Co Ltd
- XinThera Inc
- Zhejiang Yatai Pharmaceutical Co Ltd
